Glivec (STI571, imatinib), a rationally developed, targeted ... - Nature
2002年7月1日 · A lead compound identified in a screen for inhibitors of protein kinase C was optimized to give a methyl-piperazine derivative that was originally named STI571 (imatinib, …
《我不是药神》背后：“救命药”格列卫的传奇研发史
2018年7月8日 · 在2009年出版的一本名为《科学的艺术性和政治性》(The Art and Politics of Science)的书中， 小哈 回忆说，STI571是“迄今为止，展现癌症研究最基本问题的解决，会对 …
Imatinib (STI571，伊马替尼) - 仅供科研 | 酪氨酸激酶抑制剂 | MCE
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to …
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment ...
STI571 (formerly CGP57148B), is an ABL-specific inhibitor of tyrosine kinase that, in preclinical studies, selectively killed BCR-ABL-containing cells in vitro and in vivo. Clinical studies have …
STI571 (Gleevec™) as a paradigm for cancer therapy
2002年4月1日 · STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This …
STI-571: an anticancer protein-tyrosine kinase inhibitor
2003年10月3日 · STI-571 (imatinib, Gleevec, Glivec, CGP 57148) is an inhibitor of the Abl group of protein-tyrosine kinases. One of these enzymes, the Bcr-Abl oncoprotein, results from the …
伊马替尼 (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂 …
2024年9月3日 · Imatinib (STI571) 是 v-Abl、c-Kit 的多靶点抑制剂，可抑制 Bcr/Abl、v-Abl、Tel/Abl、天然 PDGFβ 受体和 c-Kit，但它不抑制 Src 家族激酶、c-Fms、Flt3、EGFR 或多种 …
STI-571: an anticancer protein-tyrosine kinase inhibitor
2003年10月3日 · STI-571 is a competitive inhibitor of Abl kinase with respect to ATP. Resistance to STI-571 is often the result of mutations in residues of the Bcr-Abl kinase that ordinarily bind …
STI571, a tyrosine kinase inhibitor for the treatment of chronic ...
STI571 (formerly CGP57148B), is an Abl-specific tyrosine kinase inhibitor that in preclinical studies selectively kills Bcr-Abl-containing cells in vitro and in vivo. The results of clinical …
STI571: targeting BCR-ABL as therapy for CML - PubMed
Therapeutic agent STI571 (signal transduction inhibitor number 571) is a rationally developed, potent, and selective inhibitor for abl tyrosine kinases, including bcr-abl, as well c-kit and the …